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in the pre-transmission season (August 2004) with Arte-
sunate + Sulphadoxine/Pyrimethamine and followed for 14
days. They were screened for malaria in the following
transmission season (October 2004). Further samples were
collected in October 2006.
Results: Detected anti-MSP3 antibodies on Day0 of treat-
ment were 41%, 20% and 12% for IgG, IgG1 and IgG3
respectively. Positive percentage on Day14 after treatment
were 25%, 12% and 9% for IgG, IgG1 and IgG3 respectively
and in 2006 were 33.3%, 21% and 6% for IgG, IgG1 and IgG3
respectively. Twenty six and 16 individuals had IgG1 or IgG3
or both on Day0 and Day14 respectively, all of them were
slide negative in the next transmission season. In October
2006, 24 had IgG1 or IgG3 or both, 19 were slide negative.
Conclusion: Pre-season treatment has no signiﬁcant
effect on the number of reactive antibodies (p > 0.05). There
was no signiﬁcant association between IgG presence and
malaria infection in 2006 (p > 0.05), despite approximately
same IgGs positivity in 2004. Anti-MSP3 IgG1 and IgG3 could
contribute to the persistence of asymptomatic low para-
sitaemia during the dry season. Different epitopes between
recombinant and natural MSP3 antigen stimulate different
IgGs response. That should be considered when assessing
vaccine trails.
doi:10.1016/j.ijid.2008.05.832
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Determination of Parasite Clearance Time in Antimalarial
Drug Trials Using Real-Time Quantitative PCR (PCR)
C.E. Oriero ∗, D. Nwakanma, S. Sesay, D. Conway
Medical Research Council Laboratories, Fajara, Gambia
Microscopy is generally relied upon for malaria diag-
nosis and determination of parasite density. However in
drug efﬁcacy trials where high throughput screening is
required, microscopy is slow, labour intensive and unable
to detect low-grade infections reliably. Estimation of par-
asite density in antimalarial drug trials is important as
endpoints such as time to parasite clearance or percentage
reduction in the initial parasitaemia level allows compar-
ison of the efﬁcacy of different drug combinations. In
this study, Real-time Quantitative PCR (qPCR) was used to
determine parasite clearance time in an efﬁcacy trial of
two antimalarial drugs, Artemether-Lumefantrine combina-
tion (Coartem®) and Pyronaridine-Artesunate combination
(Pyramax®). Blood samples were collected at 8-hourly inter-
vals following treatment from each of the 106 patients
enrolled in the study. The resulting 10 samples per patient
collected over a 3-day period were analyzed by qPCR ampli-
ﬁcation of the 18SrDNA gene to determine the time to
parasite clearance. The results indicate that low-grade par-
asitaemia (<20 parasites/L) was still detectable by qPCR in
20% of the patients up to 24 hours after they were negative
by microscopy. Our results indicate that the application of
a more sensitive parasite detection method such as qPCR,
could lead to more precise determination of the relative
efﬁcacy of antimalarial drugs.
doi:10.1016/j.ijid.2008.05.833
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Peritoneal Dialysis: A Life Saving Intervention for Acute
Renal Failure from Falciparum Malaria in a Secondary Care
Setting
A. Singh ∗, D. Singh, P. Singh
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Background: The mortality associated with severe
malaria remains high in malaria endemic regions due to
the non availability of sophisticated intensive care facilities
and limited resources. Acute renal failure from falciparum
malaria requiring renal replacement therapy portends a
grave prognosis in rural India. In a low resource country like
ours hemodialysis facilities are found only in tertiary care
centres which are inaccessible to the majority of people who
suffer from this disease.
Objective: To describe peritoneal dialysis as a relevant
alternative to hemodialysis in a secondary care setting
in rural India. Materials and methods: Case series of 13
patients admitted to the Baptist Christian hospital with
severe malaria requiring dialysis.
Results: Thirteen patents underwent peritoneal dialysis
for acute renal failure resulting from falciparum malaria. 10
were between 18—45 years of age and three were below 12
years of age. 11 had falciparum malaria while 2 had mixed
falciparum and vivax malaria. 10 were oliguric. Serum cre-
atinine levels ranged between 2.8mg% to 23.4mg%. 9 had
cerebral involvement and 9 had jaundice. Seven patients
had elevated transaminases of which ﬁve had levels more
than 200. All but one had AST more than ALT. 8 patients
had Hb less than 7 gms of which four were less than 5 gms.
10 patients had respiratory distress. All adult patients were
treated with artesunate and doxycycline, artesunate and
clindamycin were used in the pediatric age group. Continu-
ous peritoneal dialysis was carried out for an average of 4.7
days. One peritoneal dialysis was complicated by peritonitis
which resolved with antibiotics. 11 patients recovered com-
pletely while two succumbed to the disease within 24 and
48 hours of admission.
Conclusion: Peritoneal dialysis can be a life saving inter-
vention for patients with severe malaria in a secondary care
centre in rural India.
doi:10.1016/j.ijid.2008.05.834
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An effective vaccine for malaria has not yet been
developed. Passive immunotherapy with human monoclonal
antibodies may provide a valuable therapeutic alterna-
tive. A combinatorial immunoglobulin gene library was
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constructed from peripheral blood lymphocytes of eight
patients infected with Plasmodium falciparum and screened
for the production of human monoclonal antibody Fab frag-
ments to the C terminal 19-kDa fragment of P. falciparum
merozoite surface protein 1 (MSP-119). Three Fab clones rec-
ognized recombinant MSP-119 under nonreducing conditions.
Indirect immunoﬂuorescence microscopy demonstrated that
three Fab clones stained the surface of late tropho-
zoites/schizonts and merozoites. The dissociation constants
of these Fab fragments to recombinant MSP-119 ranged from
1.09× 10−9 to 2.66× 10−9 M. In order to improve the bind-
ing afﬁnity of the Fab fragments, we modiﬁed the single
amino acid in the third complementary-determining regions
of Fab heavy and light chains by using recombination PCR.
Tyr92 or Ile97 in the light chain and Val101 or Trp107 in
the heavy chain were selected and modiﬁed. While effec-
tive replacement at Tyr92 or Val101was not found, Ile97 in
the light chain and Trp107 in the heavy chain were possi-
bly substituted with Gly, Leu, Glu, Ala or Ser, and Arg or
Ser, respectively. Fabs with Ile97Leu and Trp107Ser exhibited
the improved afﬁnity compared with the original Fab. Our
study shows that the combinatorial immunoglobulin gene
library derived from malaria patients provides a powerful
tool for producing high-afﬁnity human antibodies speciﬁc for
P. falciparum.
doi:10.1016/j.ijid.2008.05.835
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ine/Pyrimethamine Molecular Resistance Marker Patterns
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Background: Anti-malarial drug resistance is a challeng-
ing problem for the global health community including
sub-Saharan Africa. Resistance to chloroquine (CQ)-ﬁrst
emerging in the 1960s-has steadily increased, and only
negligible susceptibility remains in much of the world.
Sulphadoxine/pyrimethamine (SP) replaced CQ as the
ﬁrst line therapeutic in Kenya for uncomplicated malaria
in 1998. During this’s study’s time period, 2003—2005,
anecdotal evidence indicated frequent SP treatment
failure.
Methods: To determine the malarial resistance patterns
to CQ and SP in two contrasting regions of Kenya, speci-
mens were collected from symptomatic volunteers in Malindi
and Busia. These towns represent coastal and western Kenya
respectively-the two regions of highest malaria transmission
in Kenya. DNA was isolated, and point speciﬁc polymor-
phisms known to confer resistance, Pfdhfr, Pfdhps, Pfmdr1,
and Pfcrt, were genotyped.
Results: There was over 90 percent mutation of the Pfcrt
gene (K76 locus) at both study sites which is consistent
with high CQ resistance. Likewise, SP demonstrated greater
than 75% mutation at all important resistance loci at both
sites. Speciﬁcally, a ‘‘quintuple mutant’’ (triple mutation
in Pfdhfr, Asn51Ile, Cys59Arg, Ser108Asn and Ala437Gly, Lys,
Leu540Glu mutations in Pfdhps) were detected in Malindi
and Busia.
Conclusion: Signiﬁcant resistance to CQ and SP in both
regions was observed. CQ resistance persisted despite a
decrease in drug pressure secondary to the national formu-
lary change in 1998 though it is likely that CQ is still widely
available and used as a self-medication. The discovery of
the quintuplemutation implies near-total SP resistance. This
ﬁnding was signiﬁcant because SP was the primary treatment
modality in Kenya at the time of the study, and incidentally,
this research subsequently played a signiﬁcant role in the
Health Ministry’s adoption of artemisinin-based antimalari-
als in 2005.
doi:10.1016/j.ijid.2008.05.836
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Background: Pfcrt and Pfmdr1 mutations have been
reported to be associated with chloroquine resistance, but
these reports have been inconsistent. Red cell factors,
sickle cell trait, ABO blood group antigens and glucose-
6-phosphate dehydrogenase (G6PD) deﬁciency are known
to confer some degree of resistance against malaria para-
site infection but their interplay with CQ resistance is yet
unknown. This study therefore aims at evaluating the cor-
relation of CQ resistance with Pfmdr1 mutation and certain
host factors in humans.
Methods: One hundred and twenty patients (1—15yrs)
with acute uncomplicated falciparum malaria were enrolled
into the study. They were administered standard doses
of CQ and followed up for parasitological and clini-
cal response for 14 days. Thick and thin blood ﬁlms
as well as ﬁlter paper blood samples were obtained
from patients before enrolment and during follow up.
Blood samples were collected in EDTA bottles for assess-
ment of haematological parameters. DNA was extracted
from ﬁlter paper using the methanol ﬁxation method and
used for Pfmdr1 and msp1 analyses by polymerase chain
reaction.
Results: Seventy patients were followed up to day 14.53%
of the patients were cured, with a 47% failure rate to
CQ. Although Pfmdr1Y86 was detected in majority of the
patients (19/33) with clinical failure, this was not statisti-
cally signiﬁcant (p > 0.05). 88% of the clinical failures was
due to recrudescence and this was highly signiﬁcant with
treatment outcome (p = 0.000). No signiﬁcant association
was found between Pfmdr1 alleles and red cell factors. How-
ever, individuals with HbAA were found to be 2.3 times more
likely to develop resistance to CQ treatment compared to
those having HbAS.
Conclusion: In conclusion, the prevalence of CQ resis-
tance and Pfmdr1Y86 mutation was high in this malaria
endemic setting. There was no clear inﬂuence of ABO, G6PD
